基因编辑权威指南。
菜单
首页 学习 新闻 向 Atlas 提问
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

🧭 引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

⚡ 专家观点
你已经了解生物学基础,只需内容本身——简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式

基因 · Cardiovascular

PCSK9

Proprotein convertase subtilisin/kexin type 9 — A liver gene that controls how much LDL cholesterol stays in the blood — and the target of the first attempt to treat a common chronic disease with a one-time edit.

1p32.3 cholesterolin vivobase editing
染色体 1 PCSK9 1p32.3 p q

仅为示意图——染色体臂比例为近似值,条带细节未按比例绘制。细胞遗传学位置以 NCBI Gene 公布的数据为准。

这个基因的功能

Liver cells pull LDL cholesterol out of the blood using receptors on their surface. PCSK9 destroys those receptors, so more cholesterol stays in circulation. People born with a broken PCSK9 gene have low cholesterol and appear entirely healthy — which is exactly why it is such an attractive target: nature has already run the experiment.

PCSK9, at 1p32.3, encodes a protease that binds the LDL receptor and directs it to lysosomal degradation, reducing hepatic LDL clearance. Loss-of-function variants are associated with lifelong low LDL cholesterol and reduced cardiovascular events without evident harm; gain-of-function variants cause familial hypercholesterolemia. It is validated as a drug target by approved monoclonal antibodies and siRNA medicines, and is the target of in vivo base-editing programmes intended to make the effect permanent.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.